RBC Capital Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $31
RBC Capital initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating and announces Price Target of $31.
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
JP Morgan Maintains Overweight on Edgewise Therapeutics, Lowers Price Target to $32
JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and lowers the price target from $33 to $32.
52 Biggest Movers From Friday
Gainers
Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share.